Post -transplantation Cyclophosphamide as Graft Versus Host Disease prophylaxis in Children with ß-Thalassemia Major undergoing Hematopoietic Stem Cell Transplantation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202311877246623

Enrollment

Registered

2023-11-23

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics

Interventions

Bone marrow transplantation . Post transplant Cyclophosphamide

ATG .Methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with ß-thalassemia major (Pesaro class I, II) undergoing allogeneic peripheral blood stem cell transplantation from matched related donor aged 2- 18 years.

Exclusion criteria

Exclusion criteria: i. Children with ß-thalassemia major (Pesaro class III). ii. Conditions with contraindication to cyclophosphamide use as ( systemic infections , uric acid kidney stones , inflammation of bladder with hemorrhage , obstruction of any part of the urinary tract , bloody urine , kidney disease with likely reduction in kidney function , children with a previous hypersensitivity to it .

Design outcomes

Primary

Measure	Time frame
Acute Graft versus host disease	—

Secondary

Measure	Time frame
chronic Graft versus host disease	—

Countries

Egypt

Contacts

Public Contactmohammed elshanshoury

profossor of pediatrics

elshanshory@gmail.com01005680834

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026